Kristine S. Klos, Ph.D.
Affiliations: | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Molecular Biology, OncologyGoogle:
"Kristine Klos"Parents
Sign in to add mentor| Dihua Yu | grad student | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston | |
| (Upregulation of VEGF through p70S6K in ErbB2 -mediated angiogenesis and inhibition by combined herceptin plus taxol therapy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Klos KS, Warmka JK, Drachenberg DM, et al. (2014) Building bridges toward invasion: tumor promoter treatment induces a novel protein kinase C-dependent phenotype in MCF10A mammary cell acini. Plos One. 9: e90722 |
| Liu Z, Liu H, Desai S, et al. (2013) miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. The Journal of Biological Chemistry. 288: 4334-45 |
| Klos KS, Wyszomierski SL, Sun M, et al. (2006) ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Research. 66: 2028-37 |
| Tan M, Li P, Klos KS, et al. (2005) ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Research. 65: 1858-67 |
| Zhou X, Tan M, Stone Hawthorne V, et al. (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6779-88 |
| Nagata Y, Lan KH, Zhou X, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 6: 117-27 |
| Klos KS, Yu D. (2004) Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer. Cancer Biology & Therapy. 3: 205-6 |
| Klos KS, Zhou X, Lee S, et al. (2003) Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer. 98: 1377-85 |
| Yang W, Klos KS, Zhou X, et al. (2003) ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Cancer. 98: 1123-30 |
| Lee S, Yang W, Lan KH, et al. (2002) Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Research. 62: 5703-10 |